Discover
TAK
Takeda Pharmaceutical Company Limited
17.48
5 x 17.47
6 x 17.48
bid
ask
-
0.07
0.43%
12:36 PM
timesize
| Ytd | 12.09% | |
| 1y | 21.10% |
17.45
day range
17.64
12.99
52 week range
18.90
| Open | 17.46 | Prev Close | 17.55 | Low | 17.45 | High | 17.64 | Mkt Cap | 55.61B |
| Vol | 1.30M | Avg Vol | 3.49M | EPS | 1.39 | P/E | 12.56 | Forward P/E | 32.92 |
| Beta | -0.08 | Short Ratio | 1.34 | Inst. Own | 3.13% | Dividend | 0.48 | Div Yield | 2.83 |
| Ex Div Date | 03-31 | Earning | 07-30 | 50-d Avg | 16.37 | 200-d Avg | 16.37 | 1yr Est | 21.43 |
| Income Statement | |||
| Total Revenue | 1.22T | ||
| Revenues (USD) | 7.55B | ||
| Cost of Revenue | 406.68B | ||
| Gross Profit | 813.22B | ||
| Operating Expenses | 611.81B | ||
| Research and Development Expense | 167.40B | ||
| Selling, General and Administrative Expense | 286.51B | ||
| Operating Income | 201.42B | ||
| Interest Expense | 63.85B | ||
| Income Tax Expense | 49.46B | ||
| Net Income | 113.26B | ||
| Net Income Common Stock | 113.26B | ||
| Net Income Common Stock (USD) | 700.84M | ||
| Consolidated Income | 113.32B | ||
| Net Income to Non-Controlling Interests | 60.00M | ||
| Earnings per Basic Share | 35.83 | ||
| Earnings per Basic Share (USD) | 0.22 | ||
| Earnings per Diluted Share | 35.27 | ||
| Earning Before Interest & Taxes (EBIT) | 226.56B | ||
| Earning Before Interest & Taxes (USD) | 1.40B | ||
| Weighted Average Shares | 1.58B | ||
| Balance Sheet | |||
| Cash and Equivalents | 460.98B | ||
| Cash and Equivalents (USD) | 2.85B | ||
| Investments | 539.82B | ||
| Investments Current | 66.60B | ||
| Investments Non-Current | 473.22B | ||
| Trade and Non-Trade Receivables | 930.38B | ||
| Current Assets | 3.15T | ||
| Property, Plant & Equipment Net | 2.14T | ||
| Total Assets | 15.66T | ||
| Debt Current | 630.09B | ||
| Total Debt | 5.65T | ||
| Current Liabilities | 2.76T | ||
| Debt Non-Current | 5.02T | ||
| Total Liabilities | 8.10T | ||
| Accumulated Retained Earnings (Deficit) | 667.01B | ||
| Accumulated Other Comprehensive Income | -11.05B | ||
| Shareholders Equity | 7.56T | ||
| Shareholders Equity (USD) | 46.77B | ||
| Assets Non-Current | 12.51T | ||
| Total Debt (USD) | 34.94B | ||
| Goodwill and Intangible Assets | 9.28T | ||
| Inventory | 1.45T | ||
| Liabilities Non-Current | 5.34T | ||
| Trade and Non-Trade Payables | 446.78B | ||
| Tax Assets | 564.91B | ||
| Tax Liabilities | 144.97B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 163.04B | ||
| Net Cash Flow from Financing | -180.35B | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -140.43B | ||
| Capital Expenditure | -52.71B | ||
| Net Cash Flow - Business Acquisitions and Disposals | 10.46B | ||
| Issuance (Purchase) of Equity Shares | -1.01B | ||
| Issuance (Repayment) of Debt Securities | -11.29B | ||
| Payment of Dividends & Other Cash Distributions | -150.13B | ||
| Net Cash Flow from Investing | -87.70B | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -522.00M | ||
| Net Cash Flow from Operations | 127.62B | ||
| Effect of Exchange Rate Changes on Cash | 6.36B | ||
| Share Based Compensation | 18.19B | ||